Physician profile
Laura E Pritz
NPI 1770032252
$4,738.17
in general payments reported to CMS, 2019-2025
21 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,013 · 2022: $1,431 · 2023: $936 · 2024: $946 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $924.78 | 2021-2025 | |
| Lundbeck LLC | $532.36 | 2021-2024 | Vyepti |
| Sk Life Science, INC. | $417.80 | 2021-2024 | Xcopri |
| Biohaven Pharmaceuticals, INC. | $280.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $264.47 | 2022-2023 | Xarelto |
| Argenx US, INC. | $250.01 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| E.R. Squibb & Sons, L.L.C. | $249.48 | 2022-2024 | Zeposia |
| Kyowa Kirin, INC. | $239.28 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $227.02 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $225.54 | 2022-2024 | Andexxa |
| Emd Serono, INC. | $145.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $141.66 | 2021-2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $124.74 | 2025 | Symbravo |
| Jazz Pharmaceuticals INC. | $124.74 | 2023 | |
| Livanova USA, INC. | $111.13 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $107.48 | 2022 | |
| Neurelis, INC. | $106.79 | 2024 | Valtoco |
| Chiesi USA, INC. | $104.62 | 2023 | Cleviprex |
| Biohaven Pharmaceutical Holding Company LTD. | $99.62 | 2022 | |
| Neurocrine Biosciences, INC. | $35.82 | 2023-2025 | Ongentys, Ingrezza |
| Celgene Corporation | $24.07 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Pritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.